P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Management of treatment-emergent peripheral neuropathy in multiple myeloma
Paul G. Richardson,Michel Delforge,Meral Beksac,Patrick Y. Wen,Joost L M Jongen,O. Sezer,E. Terpos,Nikhil C. Munshi,Angela Palumbo,S V Rajkumar,J L Harousseau,Philippe Moreau,Hervé Avet-Loiseau,Je-Hwan Lee,Michele Cavo,Giampaolo Merlini,Peter M. Voorhees,Wee Joo Chng,Amitabha Mazumder,Saad Z. Usmani,H. Einsele,Raymond L. Comenzo,Robert Z. Orlowski,David H. Vesole,J. J. Lahuerta,Ruben Niesvizky,David S. Siegel,M.V. Mateos,Meletios A. Dimopoulos,Sagar Lonial,Sundar Jagannath,J. Bladé,J F San Miguel,Gareth J. Morgan,Kenneth C. Anderson,Brian G.M. Durie,Pieter Sonneveld +36 more
TL;DR: The state of knowledge regarding treatment-emergent PN in MM patients and current management practices are outlined, and recommendations regarding optimal strategies for PN management during MM treatment are provided.
Journal ArticleDOI
VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.
Philippe Moreau,Cyrille Hulin,Margaret Macro,Denis Caillot,Carine Chaleteix,Murielle Roussel,Laurent Garderet,Bruno Royer,Sabine Brechignac,Mourad Tiab,Mathieu Puyade,Martine Escoffre,Anne-Marie Stoppa,Thierry Facon,Brigitte Pegourie,Driss Chaoui,Arnaud Jaccard,Borhane Slama,Gerald Marit,Karim Laribi,Pascal Godmer,Odile Luycx,Jean-Claude Eisenmann,Olivier Allangba,Mamoun Dib,Carla Araujo,Jean Fontan,Karim Belhadj,Marc Wetterwald,Véronique Dorvaux,Jean-Paul Fermand,Philippe Rodon,Brigitte Kolb,Sylvie Glaisner,Jean-Valère Malfuson,Pascal Lenain,Laetitia Biron,Lucie Planche,Hélène Caillon,Hervé Avet-Loiseau,Thomas Dejoie,Michel Attal +41 more
TL;DR: The data support the preferential use of VTD rather than VCD in preparation for ASCT, and the rate of peripheral neuropathy was significantly higher in the VTD arm than the VCD arm.
Journal ArticleDOI
The clinical presentation and prognosis of diffuse large B-cell lymphoma with t(14;18) and 8q24/c-MYC rearrangement.
Steven Le Gouill,Pascaline Talmant,Cyrille Touzeau,Anne Moreau,Richard Garand,Nadine Juge-Morineau,Fanny Gaillard,Thomas Gastinne,Noel Milpied,Philippe Moreau,Jean Luc Harousseau,Hervé Avet-Loiseau +11 more
TL;DR: It is concluded that DLBCL with concurrent t(14;18) and 8q24/c-MYC rearrangement is a subgroup of GC-DLBCLwith poor outcome and it is worth searching for the coexistence of dual translocations in Bcl-2-positive DLBCl with unusual aggressive presentation.
Journal ArticleDOI
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau,Asher Chanan-Khan,Andrew W. Roberts,Amit Agarwal,Thierry Facon,Shaji Kumar,Cyrille Touzeau,Elizabeth Punnoose,Jaclyn Cordero,Wijith Munasinghe,Jia Jia,Ahmed Salem,Ahmed Salem,Kevin J. Freise,Joel D. Leverson,Sari H. Enschede,Jeremy A. Ross,Paulo Maciag,Maria Verdugo,Simon J. Harrison,Simon J. Harrison +20 more
TL;DR: This novel combination of venetoclax with bortezomib and dexamethasone has an acceptable safety profile and promising efficacy in patients with relapsed/refractory MM.
Journal ArticleDOI
New Drugs and Novel Mechanisms of Action in Multiple Myeloma in 2013: A Report From the International Myeloma Working Group (IMWG)
Enrique M. Ocio,Paul G. Richardson,S V Rajkumar,Antonio Palumbo,M.V. Mateos,Robert Z. Orlowski,Shaji Kumar,Saad Z. Usmani,Saad Z. Usmani,D. Roodman,Ruben Niesvizky,H. Einsele,KC Anderson,Meletios A. Dimopoulos,Hervé Avet-Loiseau,Ulf-Henrik Mellqvist,Ingemar Turesson,Giampaolo Merlini,Rik Schots,Philip L. McCarthy,Leif Bergsagel,C. S. Chim,J.J. Lahuerta,Jatin P. Shah,A. Reiman,Joseph R. Mikhael,Sonja Zweegman,S. Lonial,Raymond L. Comenzo,Wee Joo Chng,Philippe Moreau,Pieter Sonneveld,Heinz Ludwig,B. Durie,J. S. Miguel +34 more
TL;DR: This work reviews the biological rationale for the use of the most important new agents for treating Multiple myeloma, and discusses data from already approved and active agents (including second- and third-generation proteasome inhibitors, immunomodulatory agents and alkylators).